Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 914 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... June 14, 2026 Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 Load more HOT NEWS Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... Olivia Newton-John Puts On Iconic ‘Grease’ Costume And Talks About Cancer... FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic...
